Valuation: Evelo Biosciences, Inc.

Market Cap 1.17M 1.01M 944K 867K 1.64M 111M 1.66M 11.13M 4.37M 55.44M 4.38M 4.28M 186M P/E 2021
-2.63x
P/E 2022 -1.23x
Enterprise Value 4.36M 3.79M 3.53M 3.24M 6.12M 417M 6.22M 41.63M 16.34M 207M 16.39M 16.03M 696M EV / Sales 2021
-
EV / Sales 2022 -
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 day-80.00%
Current month-66.67%
3 months-66.67%
6 months-50.00%
Current year-80.00%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
13.93
5 years 0
Extreme 0
254.8
10 years 0
Extreme 0
398.57
Manager TitleAgeSince
Chief Executive Officer 64 21/11/2023
Director TitleAgeSince
Director/Board Member 64 21/11/2023
Date Insider Type Main position Quantity % Market Cap.
11/7/23 A Fiscal year

Chief Financial Officer

14,811 0.0786%
11/7/23 A Fiscal year

Chief Executive Officer

2,516 0.0134%
11/7/23 A Fiscal year

Chief Technology Officer

16,413 0.0871%
Change 5-day change 1-year change 3-year change Capi.($)
-80.00%-.--%-80.00%-100.00% 5.69K
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -8.11%-3.41%+24.28%+129.33% 23.39B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2021 2022
Net sales - -
Net income -122M -106M -98.86M -90.76M -171M -11.66B -174M -1.17B -457M -5.81B -459M -449M -19.47B -115M -99.56M -92.67M -85.08M -161M -10.93B -163M -1.09B -429M -5.44B -430M -421M -18.25B
Net Debt -12.15M -10.56M -9.83M -9.02M -17.04M -1.16B -17.31M -116M -45.47M -577M -45.62M -44.62M -1.94B 3.2M 2.78M 2.59M 2.38M 4.49M 305M 4.56M 30.5M 11.97M 152M 12.01M 11.75M 510M
Logo Evelo Biosciences, Inc.
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.
Employees
66
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. EVLO Stock